Idorsia announced that the FDA after having released Tryvio (aprocitentan) from its REMS (Risk Evaluation and Mitigation Strategy) requirement (announced on March 17, 2025), has now approved the… read more.
Valneva SE announced that the Brazilian Health Regulatory Agency (ANVISA) approved Ixchiq vacccine for the prevention of disease caused by the chikungunya virus in individuals 18 years of… read more.
Johnson & Johnson MedTech announced 12-month results from the SmartfIRE study, presented as a late-breaking presentation at the annual meeting of the European Heart Rhythm Association (EHRA) in… read more.
The FDA approved neffy (epinephrine nasal spray) for the emergency treatment of allergic reactions (Type I), including those that are life-threatening (anaphylaxis), in adult and pediatric patients who… read more.
New results show Eli Lilly and Company’s Ebglyss achieved deep and sustained response for patients with moderate-to-severe atopic dermatitis (eczema) at three years. These findings from the ADjoin… read more.
Eisai Co., Ltd. and Biogen Inc. announced an update on the ongoing regulatory review of the Marketing Authorization Application for lecanemab as a treatment for early AD (mild… read more.
AbbVie announced that the EMA’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending the approval of upadacitinib (Rinvoq 15 mg, once daily) for… read more.
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. announced that the FDA has accepted its supplemental Biologics License Application (sBLA) for Ajovy (fremanezumab-vfrm) to expand the… read more.
NICE (UK): burosumab is recommended, within its marketing authorisation, for treating X‑linked hypophosphataemia (XLH) with radiographic evidence of bone disease in children aged 1 year and over, and in… read more.
Monogram Technologies Inc. an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, announced that the FDA has granted 510(k) clearance for… read more.
The first asthma patient has commenced treatment with Relovair (fluticasone furoate/vilanterol trifenatate) in an asthma exacerbation study, marking the start of the Phase III clinical development programme with… read more.
Pfizer Inc. announced that the European Commission (EC) has issued a decision amending the marketing authorization for Abrysvo the company’s bivalent respiratory syncytial virus (RSV) prefusion F (RSVpreF)… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
